论文部分内容阅读
目的探讨多柔比星长循环脂质体经乳腺导管给药后患者体内血药浓度变化的情况。方法 15名女性乳腺癌患者随机分为50、20、10 mg 3个剂量组,经乳腺导管给药,于规定的时间点采集外周静脉血,通过本实验室建立的高效液相荧光检测法测定血药浓度。结果低剂量和中剂量组血样采集时间最长至给药后96 h,给药后72 h血药浓度平均值分别达到852.91和1 148.59 ng.mL-1,高剂量组血样采集至用药后72 h,血药浓度平均值达到3 921.88 ng.mL-1。结论患者体内血药浓度与多柔比星长循环脂质体乳腺导管给药量之间存在正相关性;与传统的外周静脉滴注相比,经乳腺导管给药后,多柔比星长循环脂质体呈现不同的药动学特征。
Objective To investigate the change of plasma concentration of doxorubicin in patients with long-circulating liposomes delivered via the mammary duct. Methods Fifteen female breast cancer patients were randomly divided into three groups: 50, 20, and 10 mg, administered by the mammary duct. Peripheral venous blood was collected at the prescribed time points and determined by high performance liquid chromatography Blood concentration. Results The time of blood sampling in the low and middle dose groups was the longest, reaching to 96 h after administration, and the mean plasma concentrations reached 852.91 and 1 148.59 ng.mL-1 at 72 h after administration, respectively. The high-dose blood samples were collected to 72 h, the average blood concentration reached 3921.88 ng.mL-1. Conclusion There is a positive correlation between the concentration of drug in human body and the dose of liposomal mammary duct of long-term administration of doxorubicin. Compared with the traditional peripheral intravenous drip, after administration via mammary duct, doxorubicin Circulating liposomes exhibit different pharmacokinetic characteristics.